Immunometabolite L-2-HG promotes epigenetic modification of exhausted T cells and improves antitumor immunity.
JCI insight
Yang Y, Li X, Liu F, Ma M, Yang Y, Ruan C, Lu Y, Li X, Wang X, Shi Y, Zhang Z, Wang H, Cheng Z, Wu D.
Publication Overview
Key findings, Countstar context, and access to the original paper.
2025
Cancer Research
Immunology
No items found.
Key Finding
In a mouse melanoma tumor model, L-2-HG-treated CD8+ T cells for adoptive therapy led to significantly reduced tumor volume and significantly enhanced effector function of T cells. The study revealed that L-2-HG acted as an immune metabolite through epigenetic modifications of Tex cells.
Countstar Connection
Countstar (model not specified) measured cell concentration, viability, and size in the study's cell samples during quality assessment in the 2025 JCI insight study.
